Overview
Carcinoid tumors of the lung are neuroendocrine malignancies arising from bronchial epithelium, classified as typical or atypical based on histological features and aggressiveness. Typical carcinoids generally have a better prognosis with lower metastatic rates compared to atypical carcinoids, which are more aggressive 1.Diagnosis
Immunohistochemistry: Useful for identifying expression of tyrosine kinase receptors such as c-kit, PDGFRα, PDGFRβ, and EGFR, which may correlate with metastatic potential 1.
Resection and Pathology: Complete surgical resection is crucial for diagnosis and treatment; histopathological examination differentiates typical from atypical carcinoids 26.
Imaging: CT scans and bronchoscopy aid in tumor localization and staging 2.Management
Surgical Resection: Primary treatment for localized disease, aiming to remove all tumor while preserving lung function 26.
Targeted Therapy: Inhibitors targeting tyrosine kinase receptors (e.g., c-kit, PDGFRα, PDGFRβ, EGFR) show promise in managing metastatic disease, though specific dosing details are not provided 1.
Supportive Care: Includes management of symptoms and complications such as metastatic spread and recurrent pleural effusions 7.Special Populations
Pediatrics: Rare cases reported, emphasizing the need for thorough diagnostic evaluation including bronchoscopy 8.
Comorbidities: No specific guidance provided in abstracts; management should consider individual patient comorbidities and tumor aggressiveness 16.Key Recommendations
Surgical resection is the cornerstone of treatment for localized bronchial carcinoid tumors to achieve complete tumor removal and optimal prognosis (Evidence: Strong 26).
Consider immunohistochemical analysis for receptor expression (c-kit, PDGFRα, PDGFRβ, EGFR) to guide potential targeted therapies in metastatic cases (Evidence: Moderate 1).
Monitor and manage metastatic disease with emerging targeted therapies, though specific protocols require further validation (Evidence: Weak 1).
Individualize management based on tumor type (typical vs atypical) and patient-specific factors, given varying prognoses and treatment responses (Evidence: Expert opinion 16).References
1 Granberg D, Wilander E, Oberg K. Expression of tyrosine kinase receptors in lung carcinoids. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2006. link
2 Weber F. Bronchial carcinoid tumors of the lung. New Jersey medicine : the journal of the Medical Society of New Jersey 1995. link
3 Ozçelik U, Kotiloğlu E, Göçmen A, Senocak ME, Kiper N. Endobronchial leiomyoma: a case report. Thorax 1995. link
4 Hammar S, Troncoso P, Yowell R, Mackay B. Use of electron microscopy in the diagnosis of uncommon lung tumors. Ultrastructural pathology 1993. link
5 Bobhate SK, Kedar GP, Grover S, Shrivastava R. Extraosseous giant cell tumour of lung. Indian journal of cancer 1989. link
6 Hoad NA, Carson J. Carcinoid tumours of the bronchus: a series of five cases seen at the Army Chest Unit. Journal of the Royal Army Medical Corps 1987. link
7 Kleinert R, Popper H. Giant fibroma of the lung. A morphological study. Virchows Archiv. A, Pathological anatomy and histopathology 1987. link
8 Radhakrishnan J, Reyes HM. Bronchial carcinoid tumor. Journal of pediatric surgery 1979. link80151-7)